Preparation of Radiolabeled Zolbetuximab Targeting CLDN18.2 and Its Preliminary Evaluation for Potential Clinical Applications.
Sign Up to like & getrecommendations! Published in 2024 at "Molecular pharmaceutics"
DOI: 10.1021/acs.molpharmaceut.4c00122
Abstract: Claudin18.2 (CLDN18.2), due to its high expression in various gastric cancer tissues, is considered an optimal target for antitumor drug molecules. In this study, we obtained the labeled compounds of [125I]I-zolbetuximab using the Iodogen method.… read more here.
Keywords: cldn18; zolbetuximab; zolbetuximab targeting; preparation radiolabeled ... See more keywords